ArticleFrontiers in immunology2026
Development and preliminary evaluation of a ΔtssB-EP as a live attenuated vaccine against Edwardsiella piscicida.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Vaccination is the most effective strategy for preventing and controlling infectious diseases in aquaculture. Methods: In this study, a live attenuated mutant strain, designated ΔtssB-EP, was generated from a virulent Edwardsiella piscicida by in-frame deletion of the tssB gene, which encodes a component of the Type VI secretory system, using an allelic exchange approach. A series of Results: The precise deletion of about 506 bp was confirmed by PCR. The studies demonstrated that the ΔtssB-EP (mutant) exhibited a significant reduction in biofilm formation, along with a 2.7 log Conclusion: The results confirm significant attenuation of virulence in the ΔtssB-EP mutant, which elicited a robust immune response and conferred substantial protection against mortality from
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.